The ethical, economic, and practice management challenges associated with advanced testing increase as the technology advances.
Prenatal Genetic Testing
This first installment in a 2-part series summarizes the abilities of 4 commercially available technologies for noninvasive prenatal testing.
In a unanimous vote, a Food and Drug Administration (FDA) advisory committee has recommended that the agency give premarket approval to a human papillomavirus (HPV) DNA test as first-line screening for cervical cancer.
Massively parallel sequencing of maternal cell-free DNA (cfDNA testing) has been shown better at predicting fetal aneuploidies than standard screening in a new study among a general obstetric population. Published in The New England Journal of Medicine, the report by the CARE Study group was funded by Illumina.